Ms. Siegal has spent the past decade working in a multifaceted capacity within the emerging Psychedelic landscape. Through community outreach and crisis response at gatherings and events, she has witnessed and supported thousands of psychedelic adverse events in recreational settings. Ms. Siegal spent 5 years working on MDMA clinical trials and has firsthand experience in the potential for patient harm and adverse events in clinical and medical treatment settings. As an emerging expert in psychedelic safety and risk mitigation, Ms. Siegal will address various areas of risk and potential for client harm that might occur without proper training, oversight, patients' protections and through informed consent. This session will also discuss adverse outcomes for psychedelic patients and how we can begin to create better systems of care.
Learning Objectives:
List the various psychedelic medicines that will be accessible to patients currently and in the next 5 years along with appropriate care models
Describe the potential benefits and potential risks of integrating psychedelics into their medical practice
Demonstrate a clear understanding of adverse outcomes and how to create safety and support systems for potential patients
